{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:57:37Z","timestamp":1758981457407},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s40257-013-0054-4","type":"journal-article","created":{"date-parts":[[2014,4,28]],"date-time":"2014-04-28T08:39:55Z","timestamp":1398674395000},"page":"5-16","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of Psoriasis: Focus on Clinic-based Management with Infliximab"],"prefix":"10.1007","volume":"15","author":[{"given":"Esther","family":"de Eusebio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Carlos","family":"Armario-Hita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor Alegre","family":"de Miquel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,29]]},"reference":[{"issue":"7130","key":"54_CR1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","volume":"445","author":"MA Lowes","year":"2007","unstructured":"Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866\u201373.","journal-title":"Nature."},{"issue":"5","key":"54_CR2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section\u00a01. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826\u201350.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"54_CR3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496\u2013509.","journal-title":"N Engl J Med."},{"issue":"9583","key":"54_CR4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"CE Griffiths","year":"2007","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263\u201371.","journal-title":"Lancet."},{"issue":"5","key":"54_CR5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","volume":"58","author":"A Gottlieb","year":"2008","unstructured":"Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section\u00a02. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851\u201364.","journal-title":"J Am Acad Dermatol."},{"issue":"9","key":"54_CR6","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ad.2011.03.014","volume":"102","author":"M Ara","year":"2011","unstructured":"Ara M, Perez A, Ferrando J. Opinion of Spanish dermatologists regarding the use of biologic therapy in patients with moderate to severe psoriasis. Actas Dermosifiliogr. 2011;102(9):706\u201316.","journal-title":"Actas Dermosifiliogr."},{"issue":"5","key":"54_CR7","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaad.2004.04.014","volume":"51","author":"JM Gelfand","year":"2004","unstructured":"Gelfand JM, Feldman SR, Stern RS, et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51(5):704\u20138.","journal-title":"J Am Acad Dermatol."},{"issue":"9","key":"54_CR8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199503023320907","volume":"332","author":"MW Greaves","year":"1995","unstructured":"Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332(9):581\u20138.","journal-title":"N Engl J Med."},{"issue":"1","key":"54_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1\u201310.","journal-title":"Arch Dermatol Res."},{"key":"54_CR10","doi-asserted-by":"crossref","unstructured":"Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl. 2):ii14\u201317.","DOI":"10.1136\/ard.2004.032482"},{"issue":"7","key":"54_CR11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00128071-200304070-00001","volume":"4","author":"H Zachariae","year":"2003","unstructured":"Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol. 2003;4(7):441\u20137.","journal-title":"Am J Clin Dermatol."},{"issue":"3","key":"54_CR12","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1365-2133.2008.08727.x","volume":"159","author":"SR Feldman","year":"2008","unstructured":"Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159(3):704\u201310.","journal-title":"Br J Dermatol."},{"issue":"3","key":"54_CR13","doi-asserted-by":"crossref","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","volume":"34","author":"V Chandran","year":"2010","unstructured":"Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314\u201321.","journal-title":"J Autoimmun."},{"key":"54_CR14","doi-asserted-by":"crossref","unstructured":"Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl. 2):ii18\u201323; discussion ii4\u20135.","DOI":"10.1136\/ard.2004.033217"},{"issue":"4","key":"54_CR15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2005.03.046","volume":"53","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573.","journal-title":"J Am Acad Dermatol."},{"key":"54_CR16","doi-asserted-by":"crossref","unstructured":"Nast A, Augustin M, Boehncke WH, et al. Evidence-based (S3) guideline for the treatment of psoriasis vulgaris \u2013 Update: \u201cTherapeutic options\u201d and \u201cEfalizumab\u201d. J Dtsch Dermatol Ges \u2013 JDDG. 2010;8(1):65\u20136.","DOI":"10.1111\/j.1610-0387.2009.07312_supp.x"},{"key":"54_CR17","first-page":"111","volume":"2","author":"JD Bahner","year":"2009","unstructured":"Bahner JD, Cao LY, Korman NJ. Biologics in the management of psoriasis. Clin Cosmet Investig Dermatol. 2009;2:111\u201328.","journal-title":"Clin Cosmet Investig Dermatol."},{"issue":"Suppl. 2","key":"54_CR18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1468-3083.2011.04410.x","volume":"26","author":"K Reich","year":"2012","unstructured":"Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26(Suppl. 2):3\u201311.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"9","key":"54_CR19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.tig.2010.06.006","volume":"26","author":"ED Roberson","year":"2010","unstructured":"Roberson ED, Bowcock AM. Psoriasis genetics: breaking the barrier. Trends Genet. 2010;26(9):415\u201323.","journal-title":"Trends Genet."},{"key":"54_CR20","doi-asserted-by":"crossref","unstructured":"Nast A, Boehncke WH, Mrowietz U, et al. S3-guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges \u2013 JDDG. 2012;10(Suppl. 2):S1\u201395.","DOI":"10.1111\/j.1610-0387.2012.07919.x"},{"issue":"3","key":"54_CR21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00128071-200203030-00003","volume":"3","author":"J Cather","year":"2002","unstructured":"Cather J, Menter A. Novel therapies for psoriasis. Am J Clin Dermatol. 2002;3(3):159\u201373.","journal-title":"Am J Clin Dermatol."},{"issue":"6","key":"54_CR22","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1365-2133.2012.10895.x","volume":"166","author":"F Capon","year":"2012","unstructured":"Capon F, Barker JN. The quest for psoriasis susceptibility genes in the postgenome-wide association studies era: charting the road ahead. Br J Dermatol. 2012;166(6):1173\u20135.","journal-title":"Br J Dermatol."},{"issue":"6","key":"54_CR23","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.berh.2006.08.015","volume":"20","author":"JD Reveille","year":"2006","unstructured":"Reveille JD, Williams FM. Infection and musculoskeletal conditions: Rheumatologic complications of HIV infection. Best Practice Res Clin Rheumatol. 2006;20(6):1159\u201379.","journal-title":"Best Practice Res Clin Rheumatol."},{"issue":"5","key":"54_CR24","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/ard.2007.073932","volume":"67","author":"E Pattison","year":"2008","unstructured":"Pattison E, Harrison BJ, Griffiths CE, et al. Environmental risk factors for the development of psoriatic arthritis: results from a case\u2013control study. Ann Rheum Dis. 2008;67(5):672\u20136.","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"54_CR25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.smim.2009.04.002","volume":"21","author":"Y Li","year":"2009","unstructured":"Li Y, Begovich AB. Unraveling the genetics of complex diseases: susceptibility genes for rheumatoid arthritis and psoriasis. Semin Immunol. 2009;21(6):318\u201327.","journal-title":"Semin Immunol."},{"issue":"2","key":"54_CR26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","volume":"80","author":"M Cargill","year":"2007","unstructured":"Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80(2):273\u201390.","journal-title":"Am J Hum Genet."},{"issue":"2","key":"54_CR27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ng.311","volume":"41","author":"RP Nair","year":"2009","unstructured":"Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009;41(2):199\u2013204.","journal-title":"Nat Genet."},{"issue":"3 Pt 1","key":"54_CR28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","volume":"41","author":"SR Rapp","year":"1999","unstructured":"Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401\u20137.","journal-title":"J Am Acad Dermatol."},{"issue":"2 Suppl.","key":"54_CR29","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0190-9622(03)01136-8","volume":"49","author":"J Choi","year":"2003","unstructured":"Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003;49(2 Suppl.):S57\u201361.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"54_CR30","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1365-2133.2011.10213.x","volume":"164","author":"R Gniadecki","year":"2011","unstructured":"Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164(5):1091\u20136.","journal-title":"Br J Dermatol."},{"issue":"Suppl. 2","key":"54_CR31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1468-3083.2011.04411.x","volume":"26","author":"U Mrowietz","year":"2012","unstructured":"Mrowietz U. Implementing treatment goals for successful long-term management of psoriasis. J Eur Acad Dermatol Venereol. 2012;26(Suppl. 2):12\u201320.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"1","key":"54_CR32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","volume":"71","author":"L Gossec","year":"2012","unstructured":"Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4\u201312.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl. 2","key":"54_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","volume":"23","author":"D Pathirana","year":"2009","unstructured":"Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl. 2):1\u201370.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"3 Suppl. 66","key":"54_CR34","first-page":"S28","volume":"29","author":"C Salvarani","year":"2011","unstructured":"Salvarani C, Pipitone N, Marchesoni A, et al. Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol. 2011;29(3 Suppl. 66):S28\u201341.","journal-title":"Clin Exp Rheumatol."},{"issue":"5","key":"54_CR35","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0001-7310(09)71257-8","volume":"100","author":"L Puig","year":"2009","unstructured":"Puig L, Carrascosa JM, Dauden E, et al. Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents. Actas Dermosifiliogr. 2009;100(5):386\u2013413.","journal-title":"Actas Dermosifiliogr."},{"issue":"7","key":"54_CR36","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ad.2010.04.002","volume":"101","author":"G Carretero","year":"2010","unstructured":"Carretero G, Puig L, Dehesa L, et al. Guidelines on the use of methotrexate in psoriasis. Actas Dermosifiliogr. 2010;101(7):600\u201313.","journal-title":"Actas Dermosifiliogr."},{"key":"54_CR37","unstructured":"Sueiro JLF, Roura, Fern\u00e1ndez Sueiro JL, et al. Consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in psoriatic arthritis (in Spanish). Rheumatol Clin. 2011;7(3):179\u201388."},{"issue":"4","key":"54_CR38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0001-7310(09)70821-X","volume":"100","author":"L Puig","year":"2009","unstructured":"Puig L, Carrascosa JM, Dauden E, et al. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venerology. Actas Dermosifiliogr. 2009;100(4):277\u201386.","journal-title":"Actas Dermosifiliogr."},{"issue":"5","key":"54_CR39","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","volume":"161","author":"CH Smith","year":"2009","unstructured":"Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists\u2019 guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161(5):987\u20131019.","journal-title":"Br J Dermatol."},{"issue":"3","key":"54_CR40","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","volume":"61","author":"A Menter","year":"2009","unstructured":"Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section\u00a04. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451\u201385.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"54_CR41","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jaad.2008.12.032","volume":"60","author":"A Menter","year":"2009","unstructured":"Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section\u00a03. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643\u201359.","journal-title":"J Am Acad Dermatol."},{"key":"54_CR42","unstructured":"Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis. 2009."},{"issue":"4","key":"54_CR43","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2310\/7750.2011.10066","volume":"15","author":"K Papp","year":"2011","unstructured":"Papp K, Gulliver W, Lynde C, et al. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011;15(4):210\u20139.","journal-title":"J Cutan Med Surg."},{"issue":"1","key":"54_CR44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archdermatol.2011.1410","volume":"148","author":"S Hsu","year":"2012","unstructured":"Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148(1):95\u2013102.","journal-title":"Arch Dermatol."},{"issue":"9","key":"54_CR45","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","volume":"68","author":"CT Ritchlin","year":"2009","unstructured":"Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387\u201394.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"54_CR46","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00403-012-1214-8","volume":"304","author":"A Nast","year":"2012","unstructured":"Nast A, Boehncke WH, Mrowietz U, et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2012;304(2):87\u2013113.","journal-title":"Arch Dermatol Res."},{"issue":"9625","key":"54_CR47","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665\u201374.","journal-title":"Lancet."},{"issue":"9625","key":"54_CR48","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675\u201384.","journal-title":"Lancet."},{"issue":"5","key":"54_CR49","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semarthrit.2007.07.003","volume":"37","author":"PV Voulgari","year":"2008","unstructured":"Voulgari PV, Venetsanopoulou AI, Exarchou SA, et al. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study. Semin Arthritis Rheum. 2008;37(5):293\u20138.","journal-title":"Semin Arthritis Rheum."},{"issue":"2","key":"54_CR50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","volume":"66","author":"K Gordon","year":"2012","unstructured":"Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3\u00a0years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66(2):241\u201351.","journal-title":"J Am Acad Dermatol."},{"issue":"8","key":"54_CR51","first-page":"928","volume":"9","author":"C Leonardi","year":"2010","unstructured":"Leonardi C, Strober B, Gottlieb AB, et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol. 2010;9(8):928\u201337.","journal-title":"J Drugs Dermatol."},{"issue":"4","key":"54_CR52","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2012.10901.x","volume":"166","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3\u00a0years. Br J Dermatol. 2012;166(4):861\u201372.","journal-title":"Br J Dermatol."},{"key":"54_CR53","unstructured":"Dougherty L, Bravery K, Gabriel J, et al. Standards for infusion therapy: the RCN IV Therapy Forum. 3rd edn. January 2010."},{"key":"54_CR54","unstructured":"Pearce DJ, Boles A, Greist HM, Feldman SR. Biologic therapy for psoriasis: telephone triage. Dermatol Nurs. 2005;17(4):265\u201370; 295."},{"issue":"3","key":"54_CR55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jaad.2007.11.011","volume":"58","author":"L Clark","year":"2008","unstructured":"Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008;58(3):443\u20136.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"54_CR56","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000149970","volume":"217","author":"K Reich","year":"2008","unstructured":"Reich K, Griffiths C, Barker J, et al. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology. 2008;217(3):268\u201375.","journal-title":"Dermatology."},{"issue":"3","key":"54_CR57","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/039463200702000324","volume":"20","author":"N Cassano","year":"2007","unstructured":"Cassano N, Puglisi Guerra A, Malara C, et al. Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriatic patients. Int J Immunopathol Pharmacol. 2007;20(3):647\u201350.","journal-title":"Int J Immunopathol Pharmacol."},{"issue":"1","key":"54_CR58","first-page":"9","volume":"142","author":"G Lemme","year":"2007","unstructured":"Lemme G, Campanati A, Paolinelli M, Offidani A. Diffuse psoriasis plaque type and infliximab: our experience and review of literature. G Ital Dermatol Venerol. 2007;142(1):9\u201314.","journal-title":"G Ital Dermatol Venerol."},{"issue":"6","key":"54_CR59","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1067\/mjd.2002.120472","volume":"46","author":"RE Schopf","year":"2002","unstructured":"Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol. 2002;46(6):886\u201391.","journal-title":"J Am Acad Dermatol."},{"issue":"9271","key":"54_CR60","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","volume":"357","author":"U Chaudhari","year":"2001","unstructured":"Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357(9271):1842\u20137.","journal-title":"Lancet."},{"issue":"9494","key":"54_CR61","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","volume":"366","author":"K Reich","year":"2005","unstructured":"Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367\u201374.","journal-title":"Lancet."},{"issue":"4","key":"54_CR62","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","volume":"51","author":"AB Gottlieb","year":"2004","unstructured":"Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534\u201342.","journal-title":"J Am Acad Dermatol."},{"issue":"8","key":"54_CR63","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150\u20137.","journal-title":"Ann Rheum Dis."},{"key":"54_CR64","doi-asserted-by":"crossref","unstructured":"Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1\u00a0year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31 e1\u201315.","DOI":"10.1016\/j.jaad.2006.07.017"},{"issue":"1","key":"54_CR65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2133.2011.10583.x","volume":"166","author":"K Reich","year":"2012","unstructured":"Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol. 2012;166(1):179\u201388.","journal-title":"Br J Dermatol."},{"issue":"12","key":"54_CR66","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/2013.jamadermatol.238","volume":"148","author":"VW Lin","year":"2012","unstructured":"Lin VW, Ringold S, Devine EB. Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: a Bayesian network meta-analysis. Arch Dermatol. 2012;148(12):1403\u201310.","journal-title":"Arch Dermatol."},{"issue":"3","key":"54_CR67","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.2008.08732.x","volume":"159","author":"J Schmitt","year":"2008","unstructured":"Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159(3):513\u201326.","journal-title":"Br J Dermatol."},{"issue":"2","key":"54_CR68","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2133.2008.08673.x","volume":"159","author":"AK Brimhall","year":"2008","unstructured":"Brimhall AK, King LN, Licciardone JC, et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159(2):274\u201385.","journal-title":"Br J Dermatol."},{"key":"54_CR69","doi-asserted-by":"crossref","unstructured":"Esposito M, Gisondi P, Cassano F, et al. Survival rate of antitumour necrosis factor-\u03b1 treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013;169:666\u201372.","DOI":"10.1111\/bjd.12422"},{"issue":"4","key":"54_CR70","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40257-013-0030-z","volume":"14","author":"CS Ahn","year":"2013","unstructured":"Ahn CS, Gustafson CJ, Sandoval LF, et al. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013;14(4):315\u201326.","journal-title":"Am J Clin Dermatol."},{"issue":"1","key":"54_CR71","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jaad.2007.09.018","volume":"58","author":"AA Nelson","year":"2008","unstructured":"Nelson AA, Pearce DJ, Fleischer AB Jr, et al. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008;58(1):125\u201335.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"54_CR72","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12325-012-0007-y","volume":"29","author":"MM Bonafede","year":"2012","unstructured":"Bonafede MM, Gandra SR, Watson C, et al. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther. 2012;29(3):234\u201348.","journal-title":"Adv Ther."},{"issue":"3","key":"54_CR73","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2133.2008.08728.x","volume":"159","author":"LL Lecluse","year":"2008","unstructured":"Lecluse LL, Piskin G, Mekkes JR, et al. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008;159(3):527\u201336.","journal-title":"Br J Dermatol."},{"issue":"2","key":"54_CR74","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0001-7310(09)70227-3","volume":"100","author":"L PuigSanz","year":"2009","unstructured":"PuigSanz L, Saez E, Lozano MJ, et al. Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working Group of the Grupo Espanol de Psoriasis de la Academia Espanola de Dermatologia y Venereologia. Actas Dermosifiliogr. 2009;100(2):103\u201312.","journal-title":"Actas Dermosifiliogr."},{"issue":"2","key":"54_CR75","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2133.2012.10931.x","volume":"167","author":"JS Wee","year":"2012","unstructured":"Wee JS, Petrof G, Jackson K, et al. Infliximab for the treatment of psoriasis in the UK: a 9\u00a0year experience of infusion reactions at a single centre. Br J Dermatol. 2012;167(2):411\u20136.","journal-title":"Br J Dermatol."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-013-0054-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-013-0054-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-013-0054-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T19:12:47Z","timestamp":1565377967000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-013-0054-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":75,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["54"],"URL":"https:\/\/doi.org\/10.1007\/s40257-013-0054-4","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}